Phase 4 Trial

Phase 4 covers interventional studies run after marketing authorisation. Some are voluntary, aimed at label expansion, a new population or a head-to-head comparison a company wants for commercial reasons. Others are imposed as post-marketing requirements or commitments at approval. The category is distinct from passive pharmacovigilance, which collects spontaneous reports rather than randomising anyone, and it is also where accelerated approvals must confirm the clinical benefit their surrogate endpoint only predicted.

Post-approval studies have reversed decisions. The SCOUT trial of the weight-loss drug sibutramine, run in a high cardiovascular risk population, found excess non-fatal myocardial infarction and stroke and led to withdrawal from the European and United States markets in 2010. Cardiovascular safety questions around rosiglitazone drove label changes and prescribing restrictions. After 2008 the FDA required cardiovascular outcome trials for new type 2 diabetes drugs, which is why so many incretin agents carry a dedicated outcome study.

The value of Phase 4 is that the denominator is finally large and the population finally ordinary. Rare harms, interactions, adherence in real life and effectiveness rather than efficacy are all things a pre-approval programme is structurally unable to measure. Approval marks a point where benefit outweighed known risk on the evidence then available, not a point where the evidence stopped accumulating.

Two errors are common. The first is calling any post-approval observational analysis a Phase 4 trial; a registry review is real-world evidence, not an interventional study. The second is assuming mandated confirmatory studies get done on time, when in practice post-marketing requirements are frequently delayed for years, leaving drugs on the market with the confirmatory question still open.